<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: PIK3CA mutant and <z:mp ids='MP_0002169'>wild-type</z:mp> human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were treated in vitro with NVP-BEZ235, and the resulting effects on proliferation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and signaling were assessed </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">Colonic tumors</z:e> from a genetically engineered mouse (GEM) model for <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:mp ids='MP_0002169'>wild-type</z:mp> PIK3CA <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were treated in vivo with NVP-BEZ235 </plain></SENT>
<SENT sid="3" pm="."><plain>The resulting effects on macroscopic <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>/regression, proliferation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and signaling were examined </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In vitro treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines with NVP-BEZ235 resulted in transient PI3K blockade, sustained decreases in mTORC1/mTORC2 signaling, and a corresponding decrease in cell viability (median IC(50) = 9.0-14.3 nM) </plain></SENT>
<SENT sid="5" pm="."><plain>Similar effects were seen in paired isogenic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines that differed only in the presence or absence of an activating PIK3CA mutant allele </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo treatment of <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colonic tumor</z:e>-bearing mice with NVP-BEZ235 resulted in transient PI3K inhibition and sustained blockade of mTORC1/mTORC2 signaling </plain></SENT>
<SENT sid="7" pm="."><plain>Longitudinal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> surveillance by optical colonoscopy demonstrated a 97% increase in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size in control mice (p = 0.01) vs. a 43% decrease (p = 0.008) in treated mice </plain></SENT>
<SENT sid="8" pm="."><plain>Ex vivo analysis of the NVP-BEZ235-treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> demonstrated a 56% decrease in proliferation (p = 0.003), no effects on <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and a 75% reduction in <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> (p = 0.013) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These studies provide the preclinical rationale for studies examining the efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>